Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.

Saved in:
Bibliographic Details
Title: Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.
Authors: Langleben D (AUTHOR), Hirsch AM (AUTHOR), Shalit E (AUTHOR), Lesenko L (AUTHOR), Barst RJ (AUTHOR), Langleben, David1 (AUTHOR), Hirsch, Andrew M (AUTHOR), Shalit, Eileen (AUTHOR), Lesenko, Lyda (AUTHOR), Barst, Robyn J (AUTHOR)
Source: CHEST. Oct2004, Vol. 126 Issue 4, p1377-1381. 5p.
URL: 14957149
Database: Academic Search Ultimate
Description
ISSN:00123692
DOI:10.1378/chest.126.4.1377